Examkin

Soru

Zorluk: ZorPharmacokinetic and Pharmacodynamic Principles

A 3434-year-old man is brought to the emergency department by emergency medical services after being found unresponsive in a public restroom. On initial evaluation, his respiratory rate is 6/min6/\text{min} and he has pinpoint pupils. He is administered intravenous naloxone, which rapidly improves his respiratory effort and mental status. The patient admits to injecting heroin earlier in the day and expresses a strong desire to enter treatment for his substance use. After observing the patient for 22 hours, the physician notes that he appears calm with stable vital signs and minimal objective signs of withdrawal. To initiate medication-assisted treatment for opioid use disorder before discharge, the physician administers a dose of sublingual buprenorphine. Within 2020 minutes, the patient becomes extremely agitated, diaphoretic, and tachycardic. He complains of severe diffuse muscle aches, nausea, and abdominal cramps. Which of the following pharmacodynamic properties of the newly administered medication best explains this patient's acute deterioration?

  1. A
    Irreversible, noncompetitive antagonism at the receptor
  2. B
    Accelerated hepatic elimination of the prior substance via enzyme induction
  3. High receptor affinity and low intrinsic efficacyCevap
  4. D
    Direct activation of central alpha-2 adrenergic receptors
  5. E
    Rapid downregulation of receptor density following acute exposure

Cevap

High receptor affinity and low intrinsic efficacy
The correct answer accurately describes the unique pharmacodynamic profile of buprenorphine: high receptor affinity and low intrinsic efficacy. Buprenorphine is a partial agonist at the mu-opioid receptor. It possesses a significantly higher binding affinity for this receptor than most full agonists, such as heroin (and its active metabolites, including morphine) or methadone. When buprenorphine is administered to a patient who still has a full agonist occupying the mu-opioid receptors (even if they appear clinically stable or are experiencing only minimal withdrawal), the buprenorphine competitively and aggressively displaces the full agonist. Because buprenorphine is only a partial agonist (meaning it activates the receptor to a lesser maximal extent), the net effect is a sudden, sharp decrease in opioid receptor signaling. This precipitous drop in receptor stimulation triggers severe, acute opioid withdrawal symptoms, a phenomenon known as precipitated withdrawal.

Adım Adım Çözüm

1
Identify the patient's acute clinical presentation after receiving the new medication.
The patient rapidly developed agitation, diaphoresis, tachycardia, and muscle aches, which collectively represent the classic toxidrome of acute precipitated opioid withdrawal.
Recognizing the clinical syndrome is the mandatory first step to working backward to the underlying molecular mechanism.
2
Analyze the pharmacology of the administered drug compared to the patient's previously used substance.
Heroin (and its active metabolites) acts as a full agonist at the mu-opioid receptor. Buprenorphine is a partial agonist with very high binding affinity but lower intrinsic activity compared to full agonists.
Comparing the receptor properties of both substances explains their interaction when present at the receptor site simultaneously.
3
Determine the net effect at the receptor level when the new medication is introduced to an occupied receptor system.
Due to its high affinity, the medication competitively displaces residual full agonists from the mu-opioid receptors. Because of its low intrinsic efficacy, the overall receptor activation drops precipitously, triggering the acute withdrawal symptoms.
This specific pharmacodynamic interaction perfectly matches the rapid onset and severity of the patient's deterioration.

Anahtar Kavram

Buprenorphine is a partial mu-opioid agonist with high receptor binding affinity and low intrinsic efficacy; administering it while a full agonist is still present on the receptors displaces the full agonist, precipitously lowering net opioid signaling and triggering acute withdrawal.
Bu soruyu puanla

Konular

Pharmacokinetic and Pharmacodynamic Principles

Bu konudan daha fazla soru